CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

ConclusionsCEOP/IVE/GDP alternating regimen showed no remission or survival advantage to standard chemotherapy. Future clinical trials should aim to develop alternative regimen targeting disease biology as demonstrated by recurrent mutations in epigenetic factors.Trial registrationThe study was registered on ClinicalTrial.gov (NCT02533700) on August 27, 2015.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research